Acerca de
Nuestra Labor
Datos y herramientas
Eventos
Noticias
news-Roche-signing-header-may10

Roche extends commitment to WFH Humanitarian Aid Program

The World Federation of Hemophilia (WFH) and WFH USA are pleased to announce that Roche will extend its commitment to the WFH Humanitarian Aid Program until the end of 2028.

También disponible en: English Français

The donated non-factor replacement therapy will be used by the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with hemophilia A in countries where there is little or no access to treatment. The partnership between Roche and the WFH began in 2019 and was a milestone because it marked the first time that patients in developing countries had received access to non-factor replacement therapy. The donated treatment has since benefited more than 940 people across 30 countries.

“Our renewed commitment will allow us to continue to help people with haemophilia A most in need,” said Bill Anderson, CEO Roche Pharmaceuticals. “We are proud to be recognised by the WFH as a Visionary Contributor of the Program and are delighted to announce that our commitment to the WFH Humanitarian Aid Program has been extended until 2028.”

Cesar Garrido, WFH President, also praised Roche for extending their commitment to the global bleeding disorders community. “Last year was a record year for the WFH Humanitarian Aid Program, which continues to make life-changing treatment accessible for those who need it most,” he said. “With Roche’s continued support, we will be able to continue the important work that the Humanitarian Aid Program does, giving people with bleeding disorders the hope of leading a normal life through prophylactic treatment.”

From the WFH, Cesar Garrido, President; Eric Stolte, WFH USA President, Alain Baumann, CEO; Assad E. Haffar, MD, Medical & Humanitarian Aid Director; were present to officially sign the agreement. From the Roche team, Iqbal Mufti, Martynas Aizenas, Lutz Knabe, Tuende Czirok, Dan Freeman, Katya Moreno and Kentaro Kishi (Chugai) were present.

Acerca del Programa de Ayuda Humanitaria de la FMH

El Programa de Ayuda Humanitaria de la FMH combate la falta de acceso a la atención y el tratamiento ofreciendo un apoyo muy necesario a personas con trastornos de la coagulación hereditarios en países en vías de desarrollo. Al proporcionar un flujo más previsible y sustentable de donaciones de ayuda humanitaria, el Programa de Ayuda Humanitaria de la FMH hace posible que los pacientes tengan acceso consistente y confiable al tratamiento y la atención. Nada de esto sería posible sin el generoso apoyo de Sanofi Genzyme y Sobi, nuestras Contribuyentes Visionarias Fundadoras; de Bayer y Roche, nuestras Contribuyentes Visionarias; de Grifols, nuestra Contribuyente de Liderazgo; y de nuestras Contribuyentes, CSL Behring y Takeda. Para obtener más información sobre el Programa de Ayuda Humanitaria de la FMH visite www.treatmentforall.org.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.